CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and challenges that biopharma CEOs and presidents can relate to and should be aware of. To submit a CEO Corner article, please follow these guidelines.
Our Long Journey To FDA Approval
The financial markets, though, weren’t the cause of one of the most difficult periods I faced as CEO of AVEO Oncology. Instead, it was the decade-long journey we took to gain approval of our flagship kidney cancer drug, FOTIVDA (tivozanib), after significant regulatory and organizational setbacks.
How Diversity And Motherhood Fortified Me As A Women’s Health CEO
The lessons I have learned through my diverse background and motherhood are additive to those shared by many females who have stood up to share their perspectives and offer advice about how to break the pervasive glass ceiling.
Peeling Back The Layers Of The Digital Health Onion
Digital health has radically changed patient care globally and disrupted healthcare, whilst also increasing speed and efficiency through new healthcare models.
5 Mistakes To Avoid When Scaling Your Biotech Startup
My experiences have given me a deep well of expertise about the many factors that drive (or hinder) success as startups scale. Here are five traps founders must not fall victim to.
Why Russia’s Invasion Of Ukraine Threatens Our Vibrant Life Science Ecosystem
I posit that only pluralistic democracies committed to the rule of law can support the kind of investment and innovation our industry requires to thrive, while autocracies can’t make the same claim.
Recognizing The Value Of Biotech Partnerships In China
China’s pharmaceutical market operates under regulations that are closely aligned with world standards, and the companies making innovative in-roads into the market are fueled by regional and international biotech finance.
An Intentionally Unconventional Journey To CEO
I am glad to share my history here in hopes to spark a dialogue on how life science leaders are shaped, how contributions from “all paths” provide new perspectives, and how the benefits of nonconformity can improve future views — and functions therein — of leadership.
From CRO Executive To Biopharma CEO
Taking over the CEO position of a biopharma in the midst of COVID, I was faced with many unique challenges. While I continue to work through these challenges, I’ve developed guidelines that have played a pivotal role in navigating such transitions.
What I Learned In A French Lab That Led To My Role As A CEO
Our innovations didn’t happen overnight. From the very beginning, we knew that we would need to partner with others to be successful.
The Key To Competitive Differentiation In Life Sciences Is People
Especially in the early stage of a company, where speed and accuracy of drug development are highly valued, focusing on organizational strategies that provide differentiation enables a company to position itself as innovative.
BEYOND THE PRINTED PAGE
MAPS: Walking The Talk On Intellectual Property?4/29/2022
Did MAPS, a leader in the psychedelic medicines space, just make good on its promise to share its intellectual property, as opposed to wielding it against competitors?
Where Patients Meet Policy: The EveryLife Foundation For Rare Diseases4/1/2022
The year before he founded Ultragenyx, Emil Kakkis created the EveryLife Foundation for Rare Diseases, a nonprofit patient advocacy organization focused on the “equitable development of and access to lifesaving diagnoses, treatments, and cures.” We caught up with Annie Kennedy, chief of policy and advocacy at the EveryLife Foundation, to learn more about the issues and policies the foundation is prioritizing this year.
Ever Learn A Lesson The Hard Way?1/24/2022
Bernard Coulie, M.D., Ph.D., president and CEO of Pliant Therapeutics, a company developing treatments for fibrotic diseases, shares a lesson learned the hard way involving an exit from a previous startup.
LIFE SCIENCE LEADER BLOGS
The decision by J.P. Morgan to make the 2022 annual healthcare conference fully virtual, inspires reflection on the past and advocacy for the future, in this final blog by Rob Wright, retired chief editor, Life Science Leader.
Three biopharmaceutical executives discuss plans around their company getting back to in-office operations.